1240041-69-3

Basic information

• Product Name: C₁₁H₁₂N₂O
• Synonyms: C₁₁H₁₂N₂O
• CAS NO: 1240041-69-3
• Molecular Weight: 188.229
• Mol File: 1240041-69-3.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: C₁₁H₁₂N₂O(CAS DataBase Reference)
• NIST Chemistry Reference: C₁₁H₁₂N₂O(1240041-69-3)
• EPA Substance Registry System: C₁₁H₁₂N₂O(1240041-69-3)

Safety Data

• Hazardous Substances Data: 1240041-69-3(Hazardous Substances Data)

Upstream product

• 2627-86-3 (S)-1-phenyl-ethylamine 
• 105-56-6 ethyl 2-cyanoacetate 
• 618-36-0 rac-methylbenzylamine 
• 372-09-8 cyanoacetic acid 
• 105-34-0 methyl 2-cyanoacetate 

Downstream Products

• 1001088-91-0 (S,E)-2-cyano-3-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-phenylethyl)acrylamide 
• 1001088-90-9 (S,E)-2-cyano-3-(4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-N-(1-phenylethyl)acrylamide 
• 857064-38-1 WP 1066 
• 1567834-35-8 (2E,2′E)-3,3′-(1,3-phenylene)bis(2-cyano-N-((S)-1-phenylethyl)acrylamide) 

Relevant articles and documents

Preclinical characterization of signal transducer and activator of transcription 3 small molecule inhibitors for primary and metastatic brain cancer therapy

Signal transducer and activator of transcription 3 (STAT3) has been implicated as a hub for multiple oncogenic pathways. The constitutive activation of STAT3 is present in several cancers, including gliomas (GBMs), and is associated with poor therapeutic responses. Phosphorylation of STAT3 triggers its dimerization and nuclear transport, where it promotes the transcription of genes that stimulate tumor growth. In light of this role, inhibitors of the STAT3 pathway are attractive therapeutic targets for cancer. To this end, we evaluated the STAT3-inhibitory activities of three compounds (CPA-7 [trichloronitritodiammineplatinum(IV)], WP1066 [(S,E)-3-(6-bromopyridin-2-yl)-2- cyano-N-(1-phenylethyl)acrylamide, C17H14BrN 3O], and ML116 [4-benzyl-1-{thieno[2,3-d]pyrimidin-4-yl}piperidine, C18H19N3S]) in cultured rodent and human glioma cells, including GBM cancer stem cells. Our results demonstrate a potent induction of growth arrest in GBM cells after drug treatment with a concomitant induction of cell death. Although these compounds were effective at inhibiting STAT3 phosphorylation, they also displayed variable dose-dependent inhibition of STAT1, STAT5, and nuclear factor κ light-chain enhancer of activated B cells. The therapeutic efficacy of these compounds was further evaluated in peripheral and intracranial mouse tumor models. Whereas CPA-7 elicited regression of peripheral tumors, both melanoma and GBM, its efficacy was not evident when the tumors were implanted within the brain. Our data suggest poor permeability of this compound to tumors located within the central nervous system. WP1066 and ML116 exhibited poor in vivo efficacy. In summary, CPA-7 constitutes a powerful anticancer agent in models of peripheral solid cancers. Our data strongly support further development of CPA- 7-derived compounds with increased permeability to enhance their efficacy in primary and metastatic brain tumors. Copyright

Degrasyn-like symmetrical compounds: Possible therapeutic agents for multiple myeloma (MM-I)

A series of degrasyn-like symmetrical compounds have been designed, synthesized, and screened against B cell malignancy (multiple myeloma, mantle cell lymphoma) cell lines. The lead compounds T5165804 and CP2005 showed higher nanomolar potency against the